(Q37389496)

20 August 2017

1 reference

title

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example (English)

1 reference

20 August 2017

1 reference

Arlene R Hughes

1

1 reference

20 August 2017

Cynthia H Brothers

2

1 reference

20 August 2017

Michael Mosteller

3

1 reference

20 August 2017

William R Spreen

4

1 reference

20 August 2017

Daniel K Burns

5

1 reference

20 August 2017

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

10

1 reference

20 August 2017

225-233

1 reference

20 August 2017

2

1 reference

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

20 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

A review of drug patch testing and implications for HIV clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

New allele frequency database: http://www.allelefrequencies.net

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

HLA-B*5701 clinical testing: early experience in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.10.2.225

10.2217/14622416.10.2.225

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference